From May 10th to 11th, the 7th AstraZeneca China Ecosystem Conference with the theme of "Innovative Quality and Integrating Ecology" was held in Wuxi, Jiangsu. At the meeting, AstraZeneca worked with partners at home and abroad to achieve a number of important ecosystem cooperation results, covering innovative cancer diagnosis and treatment, chronic disease management, international overseas cooperation, talent development, sustainable development and other fields. At the main summit, Zhao Jianjun, Mayor of Wuxi, delivered a speech and launched the 2024 Cooperation Plan for Wuxi Biomedical Innovation Enterprises.
Wang Lei, Executive Vice President and President of International Business and China of AstraZeneca, said that the AstraZeneca China Ecosystem Conference has become an important platform for medical and health partners at home and abroad to seek cooperation and local innovation to connect with the world. Over the years, AstraZeneca has joined hands with government, industry, academia, research, medicine, investment and other resources to form a "troika" of medical and health innovation ecology with the China Smart Health Innovation Center, the International Life Science Innovation Park and the AstraZeneca CICC Medical Industry Fund as the pillars.
This year's conference has been fruitful. The Wuxi Biomedical Innovation Enterprise 2024 Cooperation Plan was jointly released by AstraZeneca and five local innovative enterprises in Wuxi, including Genetron Health, Guanhe Pharmaceutical, and Lingkr Medical, which will facilitate cross-border cooperation and exchanges in pharmaceutical innovation, and promote China's pharmaceutical innovation achievements and Chinese innovative enterprises to expand the international market.
Nine innovative companies, including Lingshu Medical, Feikang Biotech and Taylor's Biotech, signed a contract to settle in Wuxi International Life Science Innovation Park, continue to increase medical innovation incubation, and promote the coordinated development of regional innovation. AstraZeneca will join hands with the King Abdullah International Medical Research Center in Saudi Arabia to jointly promote in-depth cooperation between China and Saudi Arabia in the field of medical and health care.
AstraZeneca has also signed cooperation agreements with Gaw Capital Partners, Hailai Ventures, Genhouse Pharma and Guangzhou Zhongkang Digital Technology to expand cooperation in the construction of clinical centers for advanced therapy products, clinical treatment of oncology, clinical drug combination, and multidisciplinary consultation for lung cancer. At the same time, the inauguration of the Health Industry Science and Technology Innovation Talent Branch of Wuxi New Social Strata Association will further enrich the carriers of science and technology innovation talents in the medical and health industry and promote the deep integration of the health industry and other industries.
As a parallel forum of the 2024 Taihu Bay Life and Health Future Conference, the conference will set up 1 main summit and 10 sub-forums, focusing on cutting-edge topics such as the latest policy trends, international exchanges and cooperation, innovation and clinical empowerment, digital chronic disease management, innovative diagnosis and treatment of rare diseases, precision diagnosis of tumors, and patient empowerment, and continue to expand ecosystem cooperation. The conference attracted nearly 1,000 guests from home and abroad to gather in Wuxi to make suggestions and suggestions for effectively promoting the new quality development of the life and health industry with innovation as the core.
Modern Express/Hyundai+ reporter Chen Min